Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million
- POAI announces securities purchase agreement with accredited investors to purchase shares of common stock
- Company to use net proceeds from purchase agreement for general corporate purposes
- Agreement expected to raise $3.5 million through issuance of up to 1,650,165 shares of common stock or common stock equivalents
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock; the company plans to use the net proceeds from the purchase agreement for general corporate purposes.
POAI, a company that focuses on providing predictive models of tumor drug response to improve clinical outcomes for patients, provided details of the securities purchase agreement in a March 16 announcement (http://nnw.fm/r6SCU).
The company explained that “it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock and accompanying warrants.
“The warrants will be exercisable immediately at an exercise price of $1.88 per share, with one-half of the warrants to expire two years after the date of issuance, and one-half to expire five and one-half years after the date of issuance,” the statement continued. “The closing of the private placement is subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.”
The release noted that the offer and sale of the securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933 or applicable state securities laws. As a result, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
Under an agreement with the investors, however, POAI will be required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors no later than 30 days after the closing of the agreement.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- POAI announces securities purchase agreement with accredited investors to purchase shares of common stock
- Company to use net proceeds from purchase agreement for general corporate purposes
- Agreement expected to raise $3.5 million through issuance of up to 1,650,165 shares of common stock or common stock equivalents
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock; the company plans to use the net proceeds from the purchase agreement for general corporate purposes.
POAI, a company that focuses on providing predictive models of tumor drug response to improve clinical outcomes for patients, provided details of the securities purchase agreement in a March 16 announcement (http://nnw.fm/r6SCU).
The company explained that “it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock and accompanying warrants.
“The warrants will be exercisable immediately at an exercise price of $1.88 per share, with one-half of the warrants to expire two years after the date of issuance, and one-half to expire five and one-half years after the date of issuance,” the statement continued. “The closing of the private placement is subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.”
The release noted that the offer and sale of the securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933 or applicable state securities laws. As a result, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
Under an agreement with the investors, however, POAI will be required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors no later than 30 days after the closing of the agreement.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
